A phase II trial of diaziquone (AZQ) in mixed mesodermal sarcomas of the uterus. A Gynecologic Oncology Group study.
AZQ was given intravenously to 23 patients with mixed mesodermal sarcoma of the uterus refractory to conventional treatment at a dose of 22.5-30 mg/m2 q three weeks. There was one partial response lasting seven weeks and one drug-related death. Based upon the activity observed in this trial, there does not appear to be a significant role for AZQ as a salvage agent for mixed mesodermal sarcomas of the uterus at the dose and schedule tested.
Slayton
R E
RE
Department of Medicine, Rush-Presbyterian St. Luke's Medical Center, Chicago, IL.
Blessing
J A
JA
Clarke-Pearson
D
D
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001388:Aziridines / Q000009:adverse effects / Q000627:therapeutic use*; D016227:Benzoquinones / Q000009:adverse effects / Q000627:therapeutic use*; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008875:Middle Aged; D012509:Sarcoma / Q000188:drug therapy*; D014594:Uterine Neoplasms / Q000188:drug therapy*
D000970:Antineoplastic Agents; D001388:Aziridines; D016227:Benzoquinones; C029108:diaziquone